Stockholders Approve Doubling Authorized Common Stock to 600M Shares
TCRX sits 20% above its 52-week low of $0.882.
Summary
TScan Therapeutics stockholders approved an amendment to double the authorized voting common stock from 300 million to 600 million shares, providing the company with significant capacity for future capital raises.
Key Events · Corporate Governance and Compliance · TCRX
-
Authorized Shares Doubled
Stockholders approved an amendment to increase the authorized voting common stock from 300,000,000 to 600,000,000 shares, effective May 20, 2026.
-
Enables Future Capital Raises
This significant increase provides the company with substantial capacity for future equity financing, stock-based compensation, or strategic transactions.
-
Annual Meeting Results
The 2026 Annual Meeting also saw the election of two Class II directors and the ratification of Deloitte & Touche LLP as the independent auditor.
Analysis · TCRX · Life Sciences
TScan Therapeutics stockholders have approved a critical amendment to double the authorized voting common stock from 300 million to 600 million shares. This action, previously highlighted as essential for the company's financing strategy, provides substantial headroom for future capital raises. For a life sciences company, securing this flexibility is vital for funding ongoing operations and development programs, though it also enables significant potential dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.3M. The 52-week trading range was $0.88 to $2.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.